Voyager Therapeutics (NASDAQ:VYGR) Upgraded by Leerink Partnrs to Strong-Buy

Leerink Partnrs upgraded shares of Voyager Therapeutics (NASDAQ:VYGR) to a strong-buy rating in a report released on Wednesday morning, Zacks.com reports.

A number of other research firms also recently issued reports on VYGR. Leerink Partners assumed coverage on shares of Voyager Therapeutics in a report on Wednesday. They set an “outperform” rating and a $15.00 price objective on the stock. StockNews.com upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, October 11th. Wedbush decreased their price objective on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th. Finally, HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research note on Tuesday, August 20th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Voyager Therapeutics presently has an average rating of “Buy” and an average price target of $17.43.

Voyager Therapeutics Price Performance

VYGR opened at $7.91 on Wednesday. The firm has a market capitalization of $430.26 million, a PE ratio of -158.20 and a beta of 0.91. Voyager Therapeutics has a fifty-two week low of $5.71 and a fifty-two week high of $11.72. The company’s 50-day moving average is $6.48 and its 200 day moving average is $7.73.

Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Tuesday, August 6th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.20. Voyager Therapeutics had a return on equity of 3.31% and a net margin of 6.28%. The company had revenue of $29.58 million for the quarter, compared to analyst estimates of $11.52 million. During the same quarter last year, the company earned ($0.51) earnings per share. As a group, analysts expect that Voyager Therapeutics will post -1.44 EPS for the current year.

Insider Transactions at Voyager Therapeutics

In related news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the transaction, the insider now owns 86,001 shares in the company, valued at approximately $500,525.82. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 4.53% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Voyager Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Ameritas Investment Partners Inc. increased its stake in shares of Voyager Therapeutics by 49.6% in the first quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company’s stock worth $37,000 after purchasing an additional 1,300 shares in the last quarter. Plato Investment Management Ltd bought a new position in Voyager Therapeutics in the 1st quarter worth approximately $38,000. SG Americas Securities LLC purchased a new position in Voyager Therapeutics in the 2nd quarter valued at approximately $85,000. ProShare Advisors LLC bought a new stake in Voyager Therapeutics during the 1st quarter valued at $101,000. Finally, Victory Capital Management Inc. lifted its position in shares of Voyager Therapeutics by 14.5% during the second quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock worth $102,000 after acquiring an additional 1,630 shares in the last quarter. 48.03% of the stock is owned by hedge funds and other institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.